{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:33:11Z","timestamp":1761989591191,"version":"3.40.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023295","name":"SYN-ENOSIS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023295","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AEGEAS"},{"name":"IEMBITHEK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-021-00746-4","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:26:12Z","timestamp":1626776772000},"page":"319-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sentiljana","family":"Gumeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimilia D.","family":"Sklirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis P.","family":"Trougakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497\u2013506.","journal-title":"China Lancet"},{"key":"746_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/17474086.2018.1407645","volume":"11","author":"T Tadmor","year":"2018","unstructured":"Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11:57\u201370.","journal-title":"Expert Rev Hematol"},{"key":"746_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood.2020006965","volume":"136","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134\u201343.","journal-title":"Blood"},{"key":"746_CR4","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"L Scarfo","year":"2020","unstructured":"Scarfo L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354\u201363.","journal-title":"Leukemia"},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","volume":"55","author":"F Ravandi","year":"2006","unstructured":"Ravandi F, O\u2019Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55:197\u2013209.","journal-title":"Cancer Immunol Immunother"},{"key":"746_CR6","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/HS9.0000000000000547","volume":"5","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al. SARS-CoV-2 vaccines in patients with multiple myeloma. Hemasphere. 2021;5:e547.","journal-title":"Hemasphere"},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7) an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351\u201362.","journal-title":"Lancet"},{"key":"746_CR9","doi-asserted-by":"crossref","unstructured":"Gharpure R, Patel A, Link-Gelles R. First-dose COVID-19 vaccination coverage among skilled nursing facility residents and staff. JAMA 2021;325(16):1670\u20131.","DOI":"10.1001\/jama.2021.2352"},{"key":"746_CR10","doi-asserted-by":"crossref","unstructured":"Saadat S, Tehrani ZR, Logue J et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 2021;325(14):1467\u20139.","DOI":"10.1001\/jama.2021.3341"},{"key":"746_CR11","doi-asserted-by":"crossref","unstructured":"Terpos E, Trougakos IP, Apostolakou F et al. Age- and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol 2021;96(7):E257\u20139.","DOI":"10.1002\/ajh.26185"},{"key":"746_CR12","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Avivi I, Aharon A et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137(23):3165\u201373.","DOI":"10.1182\/blood.2021011568"},{"key":"746_CR13","doi-asserted-by":"crossref","unstructured":"Terpos E, Trougakos IP, Gavriatopoulou M et al. Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose. Blood 2021;137(26):3674\u20136.","DOI":"10.1182\/blood.2021011904"},{"key":"746_CR14","doi-asserted-by":"publisher","unstructured":"Harrington P, de Lavallade H, Doores KJ et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia 2021;1\u20135. https:\/\/doi.org\/10.1038\/s41375-021-01300-7.","DOI":"10.1038\/s41375-021-01300-7"},{"key":"746_CR15","doi-asserted-by":"publisher","unstructured":"Roeker LE, Knorr DA, Thompson MC et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia 2021;1\u20133. https:\/\/doi.org\/10.1038\/s41375-021-01270-w.","DOI":"10.1038\/s41375-021-01270-w"},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","volume":"14","author":"F Pimpinelli","year":"2021","unstructured":"Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14:81.","journal-title":"J Hematol Oncol"},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073\u20138.","journal-title":"Nat Biotechnol"},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439\u201350.","journal-title":"N Engl J Med"},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","volume":"118","author":"OE Yri","year":"2011","unstructured":"Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118:6769\u201371.","journal-title":"Blood"},{"key":"746_CR20","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","volume":"34","author":"LE Roeker","year":"2020","unstructured":"Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047\u20139.","journal-title":"Leukemia"},{"key":"746_CR21","doi-asserted-by":"publisher","unstructured":"Collier DA, Ferreira I, Kotagiri P et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 2021. https:\/\/doi.org\/10.1038\/s41586-021-03739-1.","DOI":"10.1038\/s41586-021-03739-1"},{"key":"746_CR22","doi-asserted-by":"publisher","unstructured":"Terpos E, Trougakos IP, Karalis V et al. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Am J Hematol 2021. https:\/\/doi.org\/10.1002\/ajh.26248.","DOI":"10.1002\/ajh.26248"},{"key":"746_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765\u201378.","journal-title":"Lancet Oncol"},{"key":"746_CR24","doi-asserted-by":"crossref","unstructured":"Palich R, Veyri M, Marot S et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol 2021;32(8):1051\u20133.","DOI":"10.1016\/j.annonc.2021.04.020"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","volume":"22","author":"B Waissengrin","year":"2021","unstructured":"Waissengrin B, Agbarya A, Safadi E, et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581\u20133.","journal-title":"Lancet Oncol"},{"key":"746_CR26","doi-asserted-by":"crossref","unstructured":"Borobia AM, Carcas AJ, Perez-Olmeda M et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 2021;398(10295):121\u201330.","DOI":"10.1016\/S0140-6736(21)01420-3"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00746-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00746-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00746-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:59:17Z","timestamp":1744189157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00746-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00746-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no relevant conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of \u201cAlexandra\u201d General Hospital, Athens, Greece (protocol code 900, 24 December 2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}